Literature DB >> 16351593

Antihypertensive treatment in patients with end-stage renal disease.

Mensura Ascerić1, Nedzad Mulabegović, Sabina Nuhbegović, Alma Nadarević, Muamera Mujcinagić-Vrabac.   

Abstract

Arterial hypertension is a common finding in patients with end stage renal disease (80% patients are hypertensive). Cardiovascular diseases are the main cause of death in haemodialysis. The present study was performed to asses' successful treatment in hypertensive chronic haemodialysis patients by ultra filtration only and ultra filtration combined with medics. We studied 80 hypertensive adult patients who had been on regular haemodialysis treatment for at least 12 months (average duration of 41 months). All subjects were divided in two different antihypertensive treatment groups including 40 subjects each. The first group of patients were treated with trandolapril and ultra filtration, and the second group of patients were only treated with ultra filtration (control group). Blood pressure measurements before and after HD sessions were performed for each patient. Blood pressure control was defined using World Health Organization criteria 140/90 mm Hg. Average systolic blood pressure levels, after haemodialysis, were in the first group of patients 146.33 +/- 9.7 mm Hg, and in the control group 157,86 +/- 10.33 mm Hg. Average diastolic blood pressure was 87.83 +/- 8.11 mm Hg in the first group of patients and, in the control group it was 91.03 +/- 10.67 mm Hg. There were significant differences between systolic blood pressure level in the first group of patients and the control group of patients as well as in diastolic blood pressure (p < 0.05). We conclude that an antihypertensive therapy by trandolapril is more effective than ultra filtration alone in hypertensive patients on chronic haemodialysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16351593      PMCID: PMC7202173          DOI: 10.17305/bjbms.2005.3225

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  13 in total

1.  Effect of on-line conductivity plasma ultrafiltrate kinetic modeling on cardiovascular stability of hemodialysis patients.

Authors:  F Locatelli; S Andrulli; S Di Filippo; B Redaelli; S Mangano; C Navino; R Ariano; M Tagliaferri; T Fidelio; M Corti; S Civardi; C Tetta
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

Review 2.  The concept of ventricular/vascular coupling: functional and structural alterations of the heart and arterial vessels go in parallel.

Authors:  G M London
Journal:  Nephrol Dial Transplant       Date:  1998-02       Impact factor: 5.992

3.  Importance of treatment time and blood pressure control in achieving long-term survival on dialysis.

Authors:  B Charra; M Calemard; G Laurent
Journal:  Am J Nephrol       Date:  1996       Impact factor: 3.754

4.  ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure.

Authors:  A I Dyadyk; A E Bagriy; I A Lebed; N F Yarovaya; E V Schukina; G G Taradin
Journal:  Nephrol Dial Transplant       Date:  1997-05       Impact factor: 5.992

5.  Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction.

Authors:  A Blumberg; W B Nelp; R M Hegstrom; B H Scribner
Journal:  Lancet       Date:  1967-07-08       Impact factor: 79.321

6.  Effect of converting enzyme inhibitors on cardiac changes in experimental uremia.

Authors:  M Rambausek; G Mall; S Kollmar; E Ritz
Journal:  Kidney Int Suppl       Date:  1988-09       Impact factor: 10.545

7.  Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure.

Authors:  S C Greaves; G D Gamble; J F Collins; G A Whalley; D N Sharpe
Journal:  Am J Kidney Dis       Date:  1994-11       Impact factor: 8.860

8.  Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy.

Authors:  G Cannella; E Paoletti; R Delfino; G Peloso; S Molinari; G B Traverso
Journal:  Kidney Int       Date:  1993-10       Impact factor: 10.612

9.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.

Authors:  R N Foley; P S Parfrey; J D Harnett; G M Kent; C J Martin; D C Murray; P E Barre
Journal:  Kidney Int       Date:  1995-01       Impact factor: 10.612

10.  Impact of left ventricular hypertrophy on survival in end-stage renal disease.

Authors:  J S Silberberg; P E Barre; S S Prichard; A D Sniderman
Journal:  Kidney Int       Date:  1989-08       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.